Search Result
Results for "
Migraine
" in MedChemExpress (MCE) Product Catalog:
1
Biochemical Assay Reagents
20
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-134992
-
|
Zavegepant; BHV-3500
|
CGRP Receptor
|
Neurological Disease
|
|
Vazegepant (Zavegepant) is an orally active calcitonin gene-related peptide CGRP receptor antagonist with potential for acute research in migraine, can be administered intranasally. CGRP is an important trigger in migraine pathophysiology .
|
-
-
- HY-109022A
-
-
-
- HY-P99019
-
|
TEV-48125
|
CGRP Receptor
|
Neurological Disease
|
|
Fremanezumab (TEV-48125) is a humanized IgG2a monoclonal antibody that selectively and potently binds to calcitonin gene-related peptide (CGRP). CGRP is a 37-amino acid neuropeptide involved in central and peripheral pathophysiological events of migraine. Fremanezumab has the potential for chronic migraine research .
|
-
-
- HY-109022
-
|
MK-8031; AGN-241689
|
CGRP Receptor
|
Neurological Disease
|
|
Atogepant (MK-8031) is an orally active and selective calcitonin gene–related peptide receptor (CGRP) antagonist. Atogepant can be used for researching migraine .
|
-
-
- HY-106736
-
|
|
Others
|
Neurological Disease
|
|
Etilefrine pivalate hydrochloride is an orally active compound and can be used for study of migraine headaches .
|
-
-
- HY-162925
-
|
|
CGRP Receptor
|
Neurological Disease
|
|
CGRP antagonist 6 (Compound 23) is a CGRP receptor antagonist (Ki: 0.84 nM). CGRP antagonist 6 can be used for research of migraine .
|
-
-
- HY-106124
-
-
-
- HY-111197
-
|
|
Others
|
Neurological Disease
|
|
LY-2300559 is a low-solubility carboxylic acid (pKa = 4.5). LY-2300559 can be used for the research of migraine .
|
-
-
- HY-105192
-
-
-
- HY-110351
-
|
PGN 1531 hydrochloride
|
Prostaglandin Receptor
|
Neurological Disease
|
|
BGC 20-1531 (PGN 1531) hydrochloride is a potent and selective prostanoid EP4 receptor antagonist, with a pKb of 7.6. BGC 20-1531 hydrochloride has the potential for the research of migraine headache .
|
-
-
- HY-114678
-
|
|
5-HT Receptor
|
Neurological Disease
|
|
LY302148 is a receptor ligand for 5-HT1F. Compared to the Emax of 5-HT, LY302148 behaves as a partial agonist for the 5-HT1F receptor. In the [ 35S]GTPγS binding assay targeting human 5-HT1F receptors, LY302148 exhibits good potency with an EC50 value of 5.23 nM. LY302148 can be used in the research of migraine .
|
-
-
- HY-19849
-
|
PGN 1531 free base
|
Prostaglandin Receptor
|
Neurological Disease
|
|
BGC-20-1531 (PGN 1531) free base is a potent and selective prostanoid EP4 receptor antagonist, with a pKB of 7.6. BGC-20-1531 free base has the potential for the research of migraine headache .
|
-
-
- HY-P9938
-
|
|
CGRP Receptor
|
Others
|
|
Erenumab is a fully human monoclonal antibody. Erenumab inhibits the calcitonin gene–related peptide (CGRP) receptor. Erenumab can be used for the prevention of episodic migraine .
|
-
-
- HY-123442
-
-
-
- HY-12713
-
|
|
Dopamine Receptor
|
Neurological Disease
|
|
Lisuride is an orally active dopamine D2 receptors agonist. Lisuride, as an ergot derivative, can be used for the research of Parkinson's disease, migraine, and high prolactin levels .
|
-
-
- HY-P99017
-
|
|
CGRP Receptor
|
Others
|
|
Eptinezumab is a humanized monoclonal antibody. Eptinezumab binds to calcitonin gene-related peptide (CGRP) and blocks its interaction with the receptor. Eptinezumab is used for the prevention of migraine in adults .
|
-
-
- HY-B1804
-
|
Trioctanoin; Glyceryl trioctanoate
|
Endogenous Metabolite
|
Neurological Disease
Inflammation/Immunology
|
|
Tricaprilin (Trioctanoin) is an orally active and well tolerated ketogenic agent that safely induces ketosis. Tricaprilin restores brain electrical activity and metabolism to help counteract neuroinflammation in migraine. Tricaprilin is promising for research of migraine prevention and Alzheimer’s disease (AD). Tricaprilin is a pure C8 medium chain triglyceride (MCT) .
|
-
-
- HY-135021
-
|
|
5-HT Receptor
|
Others
|
|
3,4-Dihydro Naratriptan is a serotonin 5-HT1-receptor agonist. 3,4-Dihydro Naratriptan exhibits selective vasoconstrictor activity. 3,4-Dihydro Naratriptan can be used for migraine diseases research .
|
-
-
- HY-P0203B
-
-
-
- HY-103574
-
|
ADX-10059 hydrochloride
|
mGluR
|
Neurological Disease
|
|
Raseglurant hydrochloride is a negative allosteric modulator of mGluR5. Raseglurant hydrochloride can be used in study migraine .
|
-
-
- HY-P99021
-
|
LY 2951742
|
CGRP Receptor
|
Neurological Disease
|
|
Galcanezumab (LY 2951742) is a humanized IgG4 monoclonal antibody against the CGRP ligand. Galcanezumab can be used for migraine or cluster headaches research .
|
-
-
- HY-10301
-
MK-3207
3 Publications Verification
|
CGRP Receptor
|
Neurological Disease
|
|
MK-3207 is an orally active, highly selective and species-specific CGRP receptor antagonist (for human CGRP receptor: IC50=0.12 nM; Ki=0.024 nM). MK-3207 can be used for migraine studies .
|
-
-
- HY-P0203
-
|
CGRP (83-119), mouse, rat
|
CGRP Receptor
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
|
|
α-CGRP (mouse, rat), a neuropeptide (calcitonin gene-related peptide (CGRP)) mainly expressed in neuromuscular junction, is a potent vasodilator. α-CGRP (mouse, rat) can lead to a fall in blood pressure and an increase in heart rate by peripheral administration, also relax colonie smooth muscle. α-CGRP (mouse, rat) has the potential in cardiovascular, pro-inflammatory, migraine and metabolic studies .
|
-
-
- HY-101698
-
|
Alnitidan
|
5-HT Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
Alniditan (Alnitidan) is a potent 5-HT1B and 5-HT1D receptors agonist, with IC50s of 1.7 nM and 1.3 nM for h5-HT1B and h5-HT1D receptors in HEK 293 cells, respectively. Alniditan has migraine-preventive effects .
|
-
-
- HY-P0203A
-
|
CGRP (83-119), mouse, rat TFA
|
CGRP Receptor
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
|
|
α-CGRP (mouse, rat) TFA, a neuropeptide (calcitonin gene-related peptide (CGRP)) mainly expressed in neuromuscular junction, is a potent vasodilator. α-CGRP (mouse, rat) TFA can lead to a fall in blood pressure and an increase in heart rate by peripheral administration, also relax colonie smooth muscle. α-CGRP (mouse, rat) TFA has the potential in cardiovascular, pro-inflammatory, migraine and metabolic studies .
|
-
-
- HY-101698B
-
|
Alnitidan dihydrochloride
|
5-HT Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
Alniditan (Alnitidan) dihydrochloride is a potent 5-HT1B and 5-HT1D receptors agonist, with IC50s of 1.7 nM and 1.3 nM for h5-HT1B and h5-HT1D receptors in HEK?293 cells, respectively. Alniditan dihydrochloride has migraine-preventive effects .
|
-
-
- HY-B1658
-
|
(R)-Frovatriptan; SB 209509; VML 251
|
5-HT Receptor
|
Neurological Disease
|
|
Frovatriptan is a potent 5-HT1B//D receptor agonist and has the highest 5-HT1B potency in the triptan class. Frovatriptan is apparently cerebroselective. Frovatriptan is efficacious and even superior in some endpoints also when taken during the headache phase in migraine attacks with aura .
|
-
-
- HY-120294
-
|
|
CGRP Receptor
TRP Channel
|
Neurological Disease
|
|
Chrysin 6-C-glucoside 8-C-arabinoside can inhibit the CGRP releasing and the activation of TRPV1 channel. Chrysin 6-C-glucoside 8-C-arabinoside can be used for anti-migraine research .
|
-
-
- HY-135809
-
|
|
Potassium Channel
|
Neurological Disease
|
|
A2764 dihydrochloride is a highly selective inhibitor of TRESK (TWIK-related spinal cord K + channel, K2P18.1), which has moderate inhibitory effects on TREK-1 and TALK-1. A2764 dihydrochloride is more sensitive to the activated mTRESK channels (IC50=6.8 μM) than the basal current. A2764 dihydrochloride can lead to cell depolarization and increased excitability in native cells, it has the potential for probing the role of TRESK channel in migraine and nociception .
|
-
-
- HY-A0039
-
|
UK-116044
|
5-HT Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
Eletriptan (UK-116044) is a highly selective and orally active serotonin 5-HT1B and 5-HT1D receptor agonist, with pKi values of 8.0 and 8.9, respectively. Eletriptan has inhibitory effects on markers of neurogenic inflammation in rats. Eletriptan can be used for researching migraine .
|
-
-
- HY-B0121B
-
|
GR 43175 free base
|
5-HT Receptor
|
Neurological Disease
|
|
Sumatriptan (GR 43175) is an orally active 5-HT1 receptor agonist with IC50s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT1D, 5-HT1B and 5-HT1F receptors, respectively. Sumatriptan can be used for migraine headache research .
|
-
-
- HY-B0121A
-
|
GR 43175 hydrochloride
|
5-HT Receptor
|
Neurological Disease
|
|
Sumatriptan hydrochloride (GR 43175) is an orally active 5-HT1 receptor agonist with IC50s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT1D, 5-HT1B and 5-HT1F receptors, respectively. Sumatriptan hydrochloride can be used for migraine headache research .
|
-
-
- HY-B0121
-
|
GR 43175 succinate
|
5-HT Receptor
|
Neurological Disease
|
|
Sumatriptan succinate (GR 43175) is an orally active 5-HT1 receptor agonist with IC50s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT1D, 5-HT1B and 5-HT1F receptors, respectively. Sumatriptan succinate can be used for migraine headache research .
|
-
-
- HY-10585R
-
|
Dipropylacetic Acid (Standard)
|
Organoid
HDAC
Autophagy
Mitophagy
HIV
Notch
Apoptosis
Endogenous Metabolite
|
Infection
Neurological Disease
Metabolic Disease
Cancer
|
|
Valproic acid (Dipropylacetic Acid) (Standard) is an analytical standard for valproic acid. This product is intended for research and analytical applications. Valproic acid is an orally active HDAC inhibitor (IC50=0.5-2 mM), inhibits the activity of HDAC1 (IC50=400 μM), and induces the degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits the proliferation of small cell lung cancer (SCLC) cells. Valproic acid is used in the study of epilepsy, bipolar disorder, metabolic diseases, HIV infection, and migraine .
|
-
-
- HY-B0121R
-
|
GR 43175 succinate (Standard)
|
5-HT Receptor
|
Neurological Disease
|
|
Sumatriptan (succinate) (Standard) is the analytical standard of Sumatriptan (succinate). This product is intended for research and analytical applications. Sumatriptan succinate (GR 43175) is an orally active 5-HT1 receptor agonist with Kis of 17 nM, 27 nM and 100 nM for 5-HT1D, 5-HT1B and 5-HT1A receptors, respectively. Sumatriptan succinate can be used for migraine headache research .
|
-
-
- HY-17494
-
|
(S)-L-714,465; MK 950 free base
|
Adrenergic Receptor
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Timolol is a β-blocker available for both topical and systemic administration. Topical Timolol is primarily used to reduce intraocular pressure with open-angle glaucoma and ocular hypertension. Timolol can also be used for the research of infantile hemangiomas, hypertension, myocardial infarction, migraine prophylaxis, and atrial fibrillation.Timolol also has cardioprotective effect .
|
-
-
- HY-B0121BS2
-
|
GR 43175 free base-d5
|
5-HT Receptor
Isotope-Labeled Compounds
|
Neurological Disease
|
|
Sumatriptan-d5 is deuterated labeled Sumatriptan (HY-B0121B). Sumatriptan (GR 43175) is an orally active 5-HT1 receptor agonist with IC50s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT1D, 5-HT1B and 5-HT1F receptors, respectively. Sumatriptan can be used for migraine headache research .
|
-
-
- HY-17494B
-
|
(S)-L-714,465 hemimaleate; MK 950 hemimaleate
|
Adrenergic Receptor
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Timolol ((S)-L-714,465; MK 950) hemimaleate is a β-blocker available for both topical and systemic administration. Topical Timolol hemimaleate is primarily used to reduce intraocular pressure with open-angle glaucoma and ocular hypertension. Timolol hemimaleate can also be used for the research of infantile hemangiomas, hypertension, myocardial infarction, migraine prophylaxis, and atrial fibrillation.Timolol also has cardioprotective effect .
|
-
-
- HY-17494R
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Timolol (Standard) is the analytical standard of Timolol. This product is intended for research and analytical applications. Timolol is a β-blocker available for both topical and systemic administration. Topical Timolol is primarily used to reduce intraocular pressure with open-angle glaucoma and ocular hypertension. Timolol can also be used for the research of infantile hemangiomas, hypertension, myocardial infarction, migraine prophylaxis, and atrial fibrillation.Timolol also has cardioprotective effect .
|
-
-
- HY-B0229
-
|
BW-311C90; 311C90
|
5-HT Receptor
Endogenous Metabolite
|
Neurological Disease
|
|
Zolmitriptan (BW-311C90; 311C90) is a 5-HT1B/1D receptor partial agonist with Kis of 5.01 nM, 0.63 nM, and 63.09 nM for 5-HT1B, 5-HT1D, 5-HT1F receptor, respectively. Zolmitriptan can be used for the research of migraine .
|
-
-
- HY-B0670A
-
-
-
- HY-10585
-
-
-
- HY-145353
-
-
-
- HY-101635
-
-
-
- HY-117694
-
|
|
CGRP Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
MK-8825 is an orally active, potent and selective CGRP receptor antagonist, which shows concentration-dependent inhibition of Capsaicin (HY-10448)-evoked dermal blood flow with an EC50 value of about 7.4 μM. MK-8825 inhibits CGRP-induced spontaneous nociceptive facial grooming behaviors, neuronal activation in the trigeminal nucleus, and systemic release of pro-inflammatory cytokines in a mouse model of acute orofacial masseteric muscle pain. MK-8825 is promising for research of acute migraine .
|
-
-
- HY-10585A
-
|
Sodium Valproate sodium
|
Organoid
HDAC
Autophagy
Mitophagy
HIV
Notch
Apoptosis
Endogenous Metabolite
|
Infection
Neurological Disease
Metabolic Disease
Cancer
|
|
Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .
|
-
-
- HY-10585B
-
|
VPA (sodium)(2:1); 2-Propylpentanoic Acid (sodium)(2:1)
|
HDAC
Autophagy
Mitophagy
HIV
Notch
Apoptosis
Endogenous Metabolite
|
Infection
Neurological Disease
Metabolic Disease
Cancer
|
|
Valproic acid (VPA) sodium (2:1) is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium (2:1) activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium (2:1) is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .
|
-
-
- HY-10585AR
-
|
|
Organoid
HDAC
Autophagy
Mitophagy
HIV
Notch
Apoptosis
Endogenous Metabolite
|
Infection
Neurological Disease
Metabolic Disease
Cancer
|
|
Valproic acid (sodium) (Standard) is the analytical standard of Valproic acid (sodium). This product is intended for research and analytical applications. Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .
|
-
-
- HY-B0197
-
|
GR-85548A
|
5-HT Receptor
|
Neurological Disease
|
|
Naratriptan is a selective 5-HT1 receptor subtype agonist and is a triptan drug that is used for the treatment of migraine headaches.
|
-
-
- HY-B0197A
-
|
GR-85548A hydrochloride
|
5-HT Receptor
|
Neurological Disease
|
|
Naratriptan hydrochloride is a selective 5-HT1 receptor subtype agonist and is a triptan drug that is used for the treatment of migraine headaches.
|
-
- HY-B1658A
-
|
(R)-Frovatriptan succinate hydrate; SB 209509 succinate hydrate; VML 251 succinate hydrate
|
5-HT Receptor
|
Neurological Disease
|
|
Frovatriptan succinate hydrate ((R)-Frovatriptan succinate hydrate) is a potent, high affinity, selective and orally active 5-HT1B (pK50 of 8.2) and 5-HT1D receptor agonist. Frovatriptan succinate hydrate exhibits >10-fold selectivity for 5-HT1B and 5-HT1D over 5-HT1A, 5-HT1F, and 5-HT7 and >1000-fold selectivity over other 5-HT, dopamine, histamine H1, and α1-adrenoceptor. Frovatriptan succinate hydrate has the potential for migraine research .
|
-
- HY-B1658B
-
|
(R)-Frovatriptan succinate; SB 209509 succinate; VML 251 succinate
|
5-HT Receptor
|
Neurological Disease
|
|
Frovatriptan succinate ((R)-Frovatriptan succinate) is a potent, high affinity, selective and orally active 5-HT1B (pK50 of 8.2) and 5-HT1D receptor agonist. Frovatriptan succinate exhibits >10-fold selectivity for 5-HT1B and 5-HT1D over 5-HT1A, 5-HT1F, and 5-HT7 and >1000-fold selectivity over other 5-HT, dopamine, histamine H1, and α1-adrenoceptor. Frovatriptan succinate has the potential for migraine research .
|
-
- HY-12366
-
-
- HY-B0383
-
-
- HY-B1658AR
-
|
|
5-HT Receptor
|
Neurological Disease
|
|
Frovatriptan (succinate hydrate) (Standard) is the analytical standard of Frovatriptan (succinate hydrate). This product is intended for research and analytical applications. Frovatriptan succinate hydrate ((R)-Frovatriptan succinate hydrate) is a potent, high affinity, selective and orally active 5-HT1B (pK50 of 8.2) and 5-HT1D receptor agonist. Frovatriptan succinate hydrate exhibits >10-fold selectivity for 5-HT1B and 5-HT1D over 5-HT1A, 5-HT1F, and 5-HT7 and >1000-fold selectivity over other 5-HT, dopamine, histamine H1, and α1-adrenoceptor. Frovatriptan succinate hydrate has the potential for migraine research .
|
-
- HY-10585G
-
|
Dipropylacetic acid
|
Organoid
HDAC
Autophagy
Mitochondrial Metabolism
HIV
Notch
Apoptosis
Endogenous Metabolite
|
Infection
Neurological Disease
Metabolic Disease
Cancer
|
|
Valproic acid (GMP) is Valproic acid (HY-10585) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Valproic acid (VPA) is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM. Valproic acid inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid is used in the epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .
|
-
- HY-100129
-
|
|
TRP Channel
|
Neurological Disease
|
|
JNJ-17203212 is a selective, potent and competitive TRPV1 antagonist. JNJ-17203212 is developed for researching pain management, such as migraine .
|
-
- HY-B0670AR
-
|
|
5-HT Receptor
|
Neurological Disease
|
|
Dihydroergotamine (mesylate) (Standard) is the analytical standard of Dihydroergotamine (mesylate). This product is intended for research and analytical applications. Dihydroergotamine mesylate is an ergot alkaloid that can be used for the research of migraines .
|
-
- HY-A0039S1
-
|
|
5-HT Receptor
|
Inflammation/Immunology
|
|
Eletriptan-d5 is the deuterium labeled Eletriptan[1]. Eletriptan (UK-116044) is a highly selective and orally active serotonin 5-HT1B and 5-HT1D receptor agonist, with pKi values of 8.0 and 8.9, respectively. Eletriptan has inhibitory effects on markers of neurogenic inflammation in rats. Eletriptan can be used for researching migraine[2].
|
-
- HY-B0383A
-
-
- HY-W335976
-
|
|
5-HT Receptor
|
Cancer
|
|
Almotriptan hydrochloride is a selective agonist of 5-HT 1B/1D Receptor. Almotriptan hydrochloride can used in study of migraine attacks .
|
-
- HY-A0039S2
-
|
|
5-HT Receptor
|
Inflammation/Immunology
|
|
Eletriptan-d5 (hydrochloride) is the deuterium labeled Eletriptan hydrochloride[1]. Eletriptan (UK-116044) hydrochloride is a highly selective and orally active serotonin 5-HT1B and 5-HT1D receptor agonist, with pKi values of 8.0 and 8.9, respectively. Eletriptan hydrochloride has inhibitory effects on markers of neurogenic inflammation in rats. Eletriptan hydrochloride can be used for researching migraine[2].
|
-
- HY-103107A
-
|
|
5-HT Receptor
|
Neurological Disease
|
|
LY334370 hydrochloride is a selective 5-HT1F receptor agonist with a Kd value of 0.446 nM. LY334370 hydrochlorid has anti-migraine activity .
|
-
- HY-B0206S
-
-
- HY-14866
-
|
ADX-10059
|
mGluR
|
Neurological Disease
|
|
Raseglurant (ADX-10059) is a mGlu5 receptor negative allosteric modulator. Raseglurant is effective against migraine. Raseglurant reduces the Haloperidol (HY-14538)-induced catalepsy in mice .
|
-
- HY-B0229S
-
-
- HY-120837
-
|
|
GABA Receptor
|
Neurological Disease
|
|
PZ-II-029 is a GABAA positive allosteric modulator that selectively binds with high affinity to α6β3γ2. PZ-II-029 shows anti-migraine effects .
|
-
- HY-12366R
-
|
|
CGRP Receptor
|
Cardiovascular Disease
Neurological Disease
|
|
Ubrogepant (Standard) is the analytical standard of Ubrogepant. This product is intended for research and analytical applications. Ubrogepant (MK-1602) is an orally active calcitonin gene-related peptide receptor (CGRP) antagonist with potential for use in acute migraine .
|
-
- HY-134992S
-
|
|
Isotope-Labeled Compounds
|
Others
|
|
(Rac)-Vazegepant- 13C,d3 is the C13 and deuterium labeled (Rac)-Vazegepant. Vazegepant (HY-134992) is the first intranasal CGRP receptor antagonist for the study the acute research of migraine .
|
-
- HY-B0383AS2
-
-
- HY-N0745
-
|
|
Caspase
|
Inflammation/Immunology
|
|
Senkyunolide I, isolated from Ligusticum chuanxiong Hort, is an anti-migraine compound. Senkyunolide I protects rat brain against focal cerebral ischemia-reperfusion injury by up-regulating p-Erk1/2, Nrf2/HO-1 and inhibiting caspase 3 .
|
-
- HY-13788
-
|
|
5-HT Receptor
Adrenergic Receptor
|
Neurological Disease
|
|
LY 344864 is a selective, orally active 5-HT1F receptor agonist with a Ki of 6 nM. LY 344864 is a full agonist producing an effect similar in magnitude to serotonin itself. LY 344864 can cross the blood brain barrier to some extent .
|
-
- HY-13788B
-
|
|
5-HT Receptor
Adrenergic Receptor
|
Neurological Disease
|
|
LY 344864 hydrochloride is a selective, orally active 5-HT1F receptor agonist with a Ki of 6 nM. LY 344864 hydrochloride is a full agonist producing an effect similar in magnitude to serotonin itself. LY 344864 hydrochloride can cross the blood brain barrier to some extent .
|
-
- HY-B1716
-
|
L-5-HTP; Oxitriptan
|
Endogenous Metabolite
|
Neurological Disease
Metabolic Disease
|
|
L-5-Hydroxytryptophan (L-5-HTP), a naturally occurring amino acid and a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid, is the immediate precursor of the neurotransmitter serotonin and a reserpine antagonist . L-5-Hydroxytryptophan (L-5-HTP) is used to treat fibromyalgia, myoclonus, migraine, and cerebellar ataxia .
|
-
- HY-103131
-
|
|
5-HT Receptor
|
Neurological Disease
|
|
PNU-142633 is a high affinity, selective and orally active 5-HT1D receptor agonist with Kis of 6 nM and > 18 000 nM for human 5-HT1D receptor and human 5-HT1B receptor, respectively. PNU-142633 has anti-migraine efficacy .
|
-
- HY-10585AS1
-
|
Sodium Valproate-d14 sodium
|
Isotope-Labeled Compounds
HDAC
Autophagy
Mitophagy
HIV
Notch
Endogenous Metabolite
|
Cancer
|
|
Valproic acid-d14 (sodium) is deuterium labeled Valproic acid (sodium). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.
|
-
- HY-B1658S
-
|
(R)-Frovatriptan-d3 hydrochloride; SB 209509-d3 hydrochloride; VML 251-d3 hydrochloride
|
5-HT Receptor
|
Neurological Disease
|
|
Frovatriptan-d3 (hydrochloride) is the deuterium labeled Frovatriptan[1]. Frovatriptan is a potent 5-HT1B//D receptor agonist and has the highest 5-HT1B potency in the triptan class. Frovatriptan is apparently cerebroselective. Frovatriptan is efficacious and even superior in some endpoints also when taken during the headache phase in migraine attacks with aura[2].
|
-
- HY-10585AS
-
|
Sodium Valproate-d7(sodium)
|
Isotope-Labeled Compounds
HDAC
Autophagy
Mitophagy
HIV
Notch
Endogenous Metabolite
|
Cancer
|
|
Valproic acid-d7 (sodium) is the deuterium labeled Valproic acid (sodium salt). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].
|
-
- HY-10585S3
-
|
VPA-d4 sodium; 2-Propylpentanoic Acid-d4 sodium
|
Isotope-Labeled Compounds
HDAC
Autophagy
Mitophagy
HIV
Notch
Endogenous Metabolite
|
Cancer
|
|
Valproic acid-d4 (sodium) is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.
|
-
- HY-10585S4
-
|
VPA-d4-1; 2-Propylpentanoic Acid-d4-1
|
Isotope-Labeled Compounds
HDAC
Autophagy
Mitophagy
HIV
Notch
Endogenous Metabolite
|
Cancer
|
|
Valproic acid-d4-1 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].
|
-
- HY-10585S2
-
|
VPA-d15; 2-Propylpentanoic Acid-d15
|
HDAC
Autophagy
Mitophagy
HIV
Notch
Endogenous Metabolite
|
Cancer
|
|
Valproic acid-d15 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].
|
-
- HY-10585S
-
|
VPA-d4; 2-Propylpentanoic Acid-d4
|
HDAC
Autophagy
Mitophagy
HIV
Notch
Endogenous Metabolite
|
Cancer
|
|
Valproic acid-d4 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].
|
-
- HY-10585S1
-
|
VPA-d6; 2-Propylpentanoic Acid-d6
|
HDAC
Autophagy
Mitophagy
HIV
Notch
Endogenous Metabolite
|
Cancer
|
|
Valproic acid-d6 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].
|
-
- HY-B0121BS
-
|
GR 43175C-d6
|
5-HT Receptor
Isotope-Labeled Compounds
|
Neurological Disease
|
|
Sumatriptan-d6 succinate is the deuterium labeled Sumatriptan succinate. Sumatriptan succinate is an orally active 5-HT1 receptor agonist with Kis of 17 nM, 27 nM and 100 nM for 5-HT1D, 5-HT1B and 5-HT1A receptors, respectively. Sumatriptan succinate can be used for migraine headache research .
|
-
- HY-19136
-
|
|
5-HT Receptor
|
Neurological Disease
|
|
WAY-100289 is an orally active antagonist for 5-HT3 receptor, that exhibits high affinity to the isolated rat vagus nerves with pA2 of 8.9. WAY-100289 inhibits the Bezold-Jarisch reflex in anesthetized and awake rats .
|
-
- HY-B1716S
-
|
L-5-HTP-d3; Oxitriptan-d3
|
Endogenous Metabolite
|
Neurological Disease
Metabolic Disease
|
|
L-5-Hydroxytryptophan-d3 is the deuterium labeled L-5-Hydroxytryptophan. L-5-Hydroxytryptophan (L-5-HTP), a naturally occurring amino acid and a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid, is the immediate precursor of the neurotransmitter serotonin and a reserpine antagonist[1]. L-5-Hydroxytryptophan (L-5-HTP) is used to treat fibromyalgia, myoclonus, migraine, and cerebellar ataxia[2][3][4][5].
|
-
- HY-B1716R
-
|
L-5-HTP (standard); Oxitriptan (standard)
|
Endogenous Metabolite
|
Neurological Disease
|
|
L-5-Hydroxytryptophan (Standard) is the analytical standard of L-5-Hydroxytryptophan. This product is intended for research and analytical applications. L-5-Hydroxytryptophan (L-5-HTP), a naturally occurring amino acid and a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid, is the immediate precursor of the neurotransmitter serotonin and a reserpine antagonist . L-5-Hydroxytryptophan (L-5-HTP) is used to treat fibromyalgia, myoclonus, migraine, and cerebellar ataxia .
|
-
- HY-B1804R
-
|
|
Endogenous Metabolite
|
Neurological Disease
Inflammation/Immunology
|
|
Tricaprilin (Standard) is the analytical standard of Tricaprilin. This product is intended for research and analytical applications. Tricaprilin (Trioctanoin) is used in study for patients with mild to moderate Alzheimer's disease and has a role as an anticonvulsant and a plant metabolite .
|
-
- HY-100942
-
|
5-CT maleate
|
5-HT Receptor
|
Neurological Disease
|
|
5-Carboxamidotryptamine maleate (5-CT maleate) is a potent 5-HT1A, 5-HT1B, 5-HT1D, 5-HT5 and 5-HT7 receptors agonist .
|
-
- HY-B1716S1
-
|
L-5-HTP-d3-1; Oxitriptan-d3-1
|
Endogenous Metabolite
|
Metabolic Disease
|
|
L-5-Hydroxytryptophan-d3-1 is the deuterium labeled L-5-Hydroxytryptophan[1]. L-5-Hydroxytryptophan (L-5-HTP), a naturally occurring amino acid and a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid, is the immediate precursor of the neurotransmitter serotonin and a reserpine antagonist[2]. L-5-Hydroxytryptophan (L-5-HTP) is used to treat fibromyalgia, myoclonus, migraine, and cerebellar ataxia[3][4][5][6].
|
-
- HY-W709349
-
|
D 9998 hydrochloride
|
Potassium Channel
iGluR
|
Inflammation/Immunology
|
|
Flupirtine hydrochloride (D 9998 hydrochloride) is a selective neuropotassium channel opener with analgesic activity. Flupirtine hydrochloride is used to inhibit a variety of pain conditions, including chronic musculoskeletal pain, migraines, and neuralgia. Flupirtine hydrochloride has antidepressant and antioxidant properties and may increase the analgesic effect in combination therapy with morphine. Flupirtine hydrochloride relieves abnormally increased muscle tension and has a muscle relaxant effect. Flupirtine hydrochloride is clinically superior to other drugs, such as tramadol and pantoxan, plus its side effects are better tolerated. Flupirtine hydrochloride has a significant effect on inhibiting neural hyperexcitability and therefore exhibits inhibitory potential in various pain states .
|
-
- HY-B1716S2
-
|
L-5-HTP-d4; Oxitriptan-d4
|
Isotope-Labeled Compounds
|
Metabolic Disease
|
|
L-5-Hydroxytryptophan-d4 (L-5-HTP-d4; Oxitriptan-d4) is a deuterium labeled L-5-Hydroxytryptophan (HY-B1716). L-5-Hydroxytryptophan (L-5-HTP), a naturally occurring amino acid and a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid, is the immediate precursor of the neurotransmitter serotonin and a reserpine antagonist . L-5-Hydroxytryptophan (L-5-HTP) is used to treat fibromyalgia, myoclonus, migraine, and cerebellar ataxia .
|
-
- HY-B1658BS
-
|
(R)-Frovatriptan-d3 succinate; SB 209509-d3 succinate; VML 251-d3 succinate
|
Isotope-Labeled Compounds
5-HT Receptor
|
Neurological Disease
|
|
Frovatriptan-d3 (succinate) is deuterium labeled Frovatriptan (succinate). Frovatriptan succinate ((R)-Frovatriptan succinate) is a potent, high affinity, selective and orally active 5-HT1B (pK50 of 8.2) and 5-HT1D receptor agonist. Frovatriptan succinate exhibits >10-fold selectivity for 5-HT1B and 5-HT1D over 5-HT1A, 5-HT1F, and 5-HT7 and >1000-fold selectivity over other 5-HT, dopamine, histamine H1, and α1-adrenoceptor. Frovatriptan succinate has the potential for migraine research[1][2].
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-10585G
-
|
Dipropylacetic acid (GMP)
|
Fluorescent Dye
|
|
Valproic acid (GMP) is Valproic acid (HY-10585) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Valproic acid (VPA) is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM. Valproic acid inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid is used in the epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .
|
| Cat. No. |
Product Name |
Type |
-
- HY-10585G
-
|
Dipropylacetic acid (GMP)
|
Biochemical Assay Reagents
|
|
Valproic acid (GMP) is Valproic acid (HY-10585) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Valproic acid (VPA) is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM. Valproic acid inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid is used in the epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P0203B
-
-
- HY-P0203
-
|
CGRP (83-119), mouse, rat
|
CGRP Receptor
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
|
|
α-CGRP (mouse, rat), a neuropeptide (calcitonin gene-related peptide (CGRP)) mainly expressed in neuromuscular junction, is a potent vasodilator. α-CGRP (mouse, rat) can lead to a fall in blood pressure and an increase in heart rate by peripheral administration, also relax colonie smooth muscle. α-CGRP (mouse, rat) has the potential in cardiovascular, pro-inflammatory, migraine and metabolic studies .
|
-
- HY-P0203A
-
|
CGRP (83-119), mouse, rat TFA
|
CGRP Receptor
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
|
|
α-CGRP (mouse, rat) TFA, a neuropeptide (calcitonin gene-related peptide (CGRP)) mainly expressed in neuromuscular junction, is a potent vasodilator. α-CGRP (mouse, rat) TFA can lead to a fall in blood pressure and an increase in heart rate by peripheral administration, also relax colonie smooth muscle. α-CGRP (mouse, rat) TFA has the potential in cardiovascular, pro-inflammatory, migraine and metabolic studies .
|
-
- HY-P2428
-
|
|
Peptides
|
Neurological Disease
|
|
RI-61 is a compound that has activity in suppressing migraine, cluster headache, new daily persistent headache and cyclical vomiting syndrome. RI-61 has shown significant efficacy in relieving the symptoms of these disorders. RI-61 helps relieve pain and other related symptoms by modulating the action of neurotransmitters .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99019
-
|
TEV-48125
|
CGRP Receptor
|
Neurological Disease
|
|
Fremanezumab (TEV-48125) is a humanized IgG2a monoclonal antibody that selectively and potently binds to calcitonin gene-related peptide (CGRP). CGRP is a 37-amino acid neuropeptide involved in central and peripheral pathophysiological events of migraine. Fremanezumab has the potential for chronic migraine research .
|
-
- HY-P9938
-
|
|
CGRP Receptor
|
Others
|
|
Erenumab is a fully human monoclonal antibody. Erenumab inhibits the calcitonin gene–related peptide (CGRP) receptor. Erenumab can be used for the prevention of episodic migraine .
|
-
- HY-P99017
-
|
|
CGRP Receptor
|
Others
|
|
Eptinezumab is a humanized monoclonal antibody. Eptinezumab binds to calcitonin gene-related peptide (CGRP) and blocks its interaction with the receptor. Eptinezumab is used for the prevention of migraine in adults .
|
-
- HY-P99021
-
|
LY 2951742
|
CGRP Receptor
|
Neurological Disease
|
|
Galcanezumab (LY 2951742) is a humanized IgG4 monoclonal antibody against the CGRP ligand. Galcanezumab can be used for migraine or cluster headaches research .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-10585AS1
-
|
|
|
Valproic acid-d14 (sodium) is deuterium labeled Valproic acid (sodium). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.
|
-
-
- HY-B0121BS2
-
|
|
|
Sumatriptan-d5 is deuterated labeled Sumatriptan (HY-B0121B). Sumatriptan (GR 43175) is an orally active 5-HT1 receptor agonist with IC50s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT1D, 5-HT1B and 5-HT1F receptors, respectively. Sumatriptan can be used for migraine headache research .
|
-
-
- HY-A0039S1
-
|
|
|
Eletriptan-d5 is the deuterium labeled Eletriptan[1]. Eletriptan (UK-116044) is a highly selective and orally active serotonin 5-HT1B and 5-HT1D receptor agonist, with pKi values of 8.0 and 8.9, respectively. Eletriptan has inhibitory effects on markers of neurogenic inflammation in rats. Eletriptan can be used for researching migraine[2].
|
-
-
- HY-A0039S2
-
|
|
|
Eletriptan-d5 (hydrochloride) is the deuterium labeled Eletriptan hydrochloride[1]. Eletriptan (UK-116044) hydrochloride is a highly selective and orally active serotonin 5-HT1B and 5-HT1D receptor agonist, with pKi values of 8.0 and 8.9, respectively. Eletriptan hydrochloride has inhibitory effects on markers of neurogenic inflammation in rats. Eletriptan hydrochloride can be used for researching migraine[2].
|
-
-
- HY-B0206S
-
|
|
|
Rizatriptan-d6 (benzoate) is the deuterium labeled Rizatriptan benzoate. Rizatriptan benzoate is a 5-HT1 agonist triptan agent for the treatment of migraine headaches[1][2].
|
-
-
- HY-B0229S
-
|
|
|
Zolmitriptan-d6 is deuterium labeled Zolmitriptan. Zolmitriptan (BW-311C90; 311C90) is a 5-HT1B/1D receptor partial agonist with Kis of 5.01 nM, 0.63 nM, and 63.09 nM for 5-HT1B, 5-HT1D, 5-HT1F receptor, respectively. Zolmitriptan can be used for the research of migraine[1][2].
|
-
-
- HY-134992S
-
|
|
|
(Rac)-Vazegepant- 13C,d3 is the C13 and deuterium labeled (Rac)-Vazegepant. Vazegepant (HY-134992) is the first intranasal CGRP receptor antagonist for the study the acute research of migraine .
|
-
-
- HY-B0383AS2
-
|
|
|
Almotriptan-d3 benzoate is deuterated labeled Almotriptan (HY-B0383A). Almotriptan is a selective agonist of 5-HT 1B/1D Receptor. Almotriptan can used in study of migraine attacks .
|
-
-
- HY-B1658S
-
|
|
|
Frovatriptan-d3 (hydrochloride) is the deuterium labeled Frovatriptan[1]. Frovatriptan is a potent 5-HT1B//D receptor agonist and has the highest 5-HT1B potency in the triptan class. Frovatriptan is apparently cerebroselective. Frovatriptan is efficacious and even superior in some endpoints also when taken during the headache phase in migraine attacks with aura[2].
|
-
-
- HY-10585AS
-
|
|
|
Valproic acid-d7 (sodium) is the deuterium labeled Valproic acid (sodium salt). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].
|
-
-
- HY-10585S3
-
|
|
|
Valproic acid-d4 (sodium) is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.
|
-
-
- HY-10585S4
-
|
|
|
Valproic acid-d4-1 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].
|
-
-
- HY-10585S2
-
|
|
|
Valproic acid-d15 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].
|
-
-
- HY-10585S
-
|
|
|
Valproic acid-d4 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].
|
-
-
- HY-10585S1
-
|
|
|
Valproic acid-d6 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches[1][2].
|
-
-
- HY-B0121BS
-
|
|
|
Sumatriptan-d6 succinate is the deuterium labeled Sumatriptan succinate. Sumatriptan succinate is an orally active 5-HT1 receptor agonist with Kis of 17 nM, 27 nM and 100 nM for 5-HT1D, 5-HT1B and 5-HT1A receptors, respectively. Sumatriptan succinate can be used for migraine headache research .
|
-
-
- HY-B1716S
-
|
|
|
L-5-Hydroxytryptophan-d3 is the deuterium labeled L-5-Hydroxytryptophan. L-5-Hydroxytryptophan (L-5-HTP), a naturally occurring amino acid and a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid, is the immediate precursor of the neurotransmitter serotonin and a reserpine antagonist[1]. L-5-Hydroxytryptophan (L-5-HTP) is used to treat fibromyalgia, myoclonus, migraine, and cerebellar ataxia[2][3][4][5].
|
-
-
- HY-B1716S1
-
|
|
|
L-5-Hydroxytryptophan-d3-1 is the deuterium labeled L-5-Hydroxytryptophan[1]. L-5-Hydroxytryptophan (L-5-HTP), a naturally occurring amino acid and a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid, is the immediate precursor of the neurotransmitter serotonin and a reserpine antagonist[2]. L-5-Hydroxytryptophan (L-5-HTP) is used to treat fibromyalgia, myoclonus, migraine, and cerebellar ataxia[3][4][5][6].
|
-
-
- HY-B1716S2
-
|
|
|
L-5-Hydroxytryptophan-d4 (L-5-HTP-d4; Oxitriptan-d4) is a deuterium labeled L-5-Hydroxytryptophan (HY-B1716). L-5-Hydroxytryptophan (L-5-HTP), a naturally occurring amino acid and a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid, is the immediate precursor of the neurotransmitter serotonin and a reserpine antagonist . L-5-Hydroxytryptophan (L-5-HTP) is used to treat fibromyalgia, myoclonus, migraine, and cerebellar ataxia .
|
-
-
- HY-B1658BS
-
|
|
|
Frovatriptan-d3 (succinate) is deuterium labeled Frovatriptan (succinate). Frovatriptan succinate ((R)-Frovatriptan succinate) is a potent, high affinity, selective and orally active 5-HT1B (pK50 of 8.2) and 5-HT1D receptor agonist. Frovatriptan succinate exhibits >10-fold selectivity for 5-HT1B and 5-HT1D over 5-HT1A, 5-HT1F, and 5-HT7 and >1000-fold selectivity over other 5-HT, dopamine, histamine H1, and α1-adrenoceptor. Frovatriptan succinate has the potential for migraine research[1][2].
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
